<div id="readability-page-1"><p><span>Cardlytics (NASDAQ:CDLX - Get Free Report)</span> was upgraded by stock analysts at Craig Hallum from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a research note issued on Wednesday,Zacks.com reports.</p><p>A number of other analysts also recently issued reports on CDLX. Lake Street Capital downgraded Cardlytics from a &#34;buy&#34; rating to a &#34;hold&#34; rating and reduced their price objective for the stock from $18.00 to $5.00 in a research note on Thursday, August 8th. Evercore ISI began coverage on Cardlytics in a report on Friday, October 11th. They issued an &#34;in-line&#34; rating and a $4.00 target price for the company. Northland Securities cut Cardlytics from an &#34;outperform&#34; rating to a &#34;market perform&#34; rating and dropped their target price for the stock from $7.00 to $5.00 in a report on Friday, August 16th. Bank of America cut Cardlytics from a &#34;neutral&#34; rating to an &#34;underperform&#34; rating and dropped their target price for the stock from $4.00 to $3.50 in a report on Thursday, August 15th. Finally, Needham &amp; Company LLC  reiterated a &#34;hold&#34; rating on shares of Cardlytics in a report on Thursday. One investment analyst  has rated the stock with a sell rating, five have issued  a hold rating and one  has given a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of &#34;Hold&#34; and a consensus price target of $6.92.</p><p><b>Check Out Our Latest Analysis on Cardlytics</b></p><h2>Cardlytics Stock Down 21.9 %</h2><p>Shares of CDLX opened at $4.07 on Wednesday. The business's 50 day moving average is $3.68 and its 200 day moving average is $6.76. The company has a market capitalization of $202.85 million, a PE ratio of -1.06 and a beta of 1.61. Cardlytics has a 12-month low of $2.89 and a 12-month high of $20.52. The company has a current ratio of 1.77, a quick ratio of 1.77 and a debt-to-equity ratio of 1.01. </p><p>Cardlytics (NASDAQ:CDLX - Get Free Report) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.21) by $0.12. Cardlytics had a negative return on equity of 17.96% and a negative net margin of 50.21%. The business had revenue of $69.64 million for the quarter, compared to the consensus estimate of $75.39 million. During the same quarter in the previous year, the company posted ($0.57) EPS. The company's revenue was down 9.2% compared to the same quarter last year.  Research analysts expect that  Cardlytics will post -1.72 earnings per share for the current fiscal year. </p><h2>Insider Activity at Cardlytics</h2><p>In other Cardlytics news, Director Scott A. Hill acquired 40,000 shares of the company's stock in a transaction that occurred on Monday, August 12th. The stock was bought at an average price of $3.58 per share, for a total transaction of $143,200.00. Following the acquisition, the director now directly owns 40,000 shares in the company, valued at $143,200. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available at this hyperlink. In other news, CEO Amit Gupta sold 22,607 shares of the stock in a transaction on Thursday, October 24th. The stock was sold at an average price of $3.85, for a total transaction of $87,036.95. Following the transaction, the chief executive officer now owns 178,519 shares of the company's stock, valued at approximately $687,298.15. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which can be accessed through this link. Also, Director Scott A. Hill purchased 40,000 shares of the company's stock in a transaction dated Monday, August 12th. The shares were purchased at an average cost of $3.58 per share, for a total transaction of $143,200.00. Following the transaction, the director now directly owns 40,000 shares in the company, valued at approximately $143,200. The disclosure for this purchase can be found here. Insiders sold a total of 43,573 shares of company stock worth $151,612 in the last quarter. 4.40% of the stock is owned by company insiders. </p><h2>Hedge Funds Weigh In On Cardlytics</h2><p>A number of hedge funds and other institutional investors have recently made changes to their positions in CDLX. Canton Hathaway LLC grew its position in shares of  Cardlytics by 95.7% during the 2nd quarter. Canton Hathaway LLC now owns 4,500 shares of the company's stock worth $37,000 after buying an additional 2,200 shares in the last quarter.  SG Americas Securities LLC bought a new position in shares of  Cardlytics during the 3rd quarter worth $45,000.  Creative Planning grew its position in shares of  Cardlytics by 35.4% during the 3rd quarter. Creative Planning now owns 29,537 shares of the company's stock worth $95,000 after buying an additional 7,721 shares in the last quarter.  XTX Topco Ltd bought a new position in shares of  Cardlytics during the 2nd quarter worth $107,000.  Finally, Quest Partners LLC boosted its position in  Cardlytics by 160.4% during the second quarter. Quest Partners LLC now owns 17,956 shares of the company's stock valued at $147,000 after purchasing an additional 11,061 shares in the last quarter. Institutional investors own  68.10% of the company's stock. </p><h2>Cardlytics Company Profile</h2> (Get Free Report)<p>Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.</p><h2>Recommended Stories</h2><ul><li>Five stocks we like better than Cardlytics</li><li>Pros And Cons Of Monthly Dividend Stocks</li><li>Gilead’s Stock Surge: What’s Fueling the Momentum?</li><li>Dividend Payout Ratio Calculator</li><li>Breakout Alert: Qualcomm Just Hit The Rally Button</li><li>ESG Stocks, What Investors Should Know</li><li>Mercado Libre Shares Go on Sale: Is Now the Time to Buy?</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0RMWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0RMWA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><p>→ Ex WH Advisor Who Predicted Biden Leaving Race Makes Startling New Prediction <span><span>(From Paradigm Press)</span> <span>(Ad)</span></span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMDM5Mg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMDM5Mg"/></p><h2>Should you invest $1,000 in Cardlytics right now?</h2><p>Before you consider Cardlytics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cardlytics wasn't on the list.</p><p>While Cardlytics currently has a &#34;Reduce&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

CDLX

<p>Craig Hallum upgraded Cardlytics (NASDAQ:CDLX) from a "hold" to a "strong-buy" rating in a recent report. Other analysts have mixed views, with Lake Street Capital downgrading the stock to "hold" and Bank of America to "underperform." Cardlytics shares opened at $0.07, down 21.9%, with a market cap of $85 million. The company reported a quarterly EPS of -$0.09, exceeding estimates, but revenue fell 9.2% year-over-year. Insider trading activity includes a director purchasing 40,000 shares and the CEO selling 22,607 shares.</p>

Cardlytics (NASDAQ:CDLX) Stock Rating Upgraded by Craig Hallum